



Atty. Docket No.: 9000/2023

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Falt, et al.
Serial No.: 10/676,424
Filed: October 1, 2003
Entitled: METHOD FOR IDENTIFICATION
OF BIOLOGICALLY ACTIVE
AGENTS

Examiner: Not Yet Assigned

Group Art Unit: 1638

Conf. No.: 1506

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Brenda M. Woods

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of Cited References; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 9000/2023. A duplicate of this transmittal letter is enclosed for this purpose.

Date: 4/15/04

Respectfully submitted,

[Signature]

Name: Matthew M. Beaudet

Registration No.: 50,649

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.: 9000/2023

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Falt, et al.
Serial No.: 10/676,424
Filed: October 1, 2003
Entitled: METHOD FOR IDENTIFICATION
OF BIOLOGICALLY ACTIVE
AGENTS

Examiner: Not Yet Assigned
Group Art Unit: 1638
Conf. No.: 1506

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: 4/15/04

Respectfully submitted,

Name: Matthew M. Beaudet
Registration No.: 50,649
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100



U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 9000/2023		Serial No. 10/676,424	
INFORMATION DISCLOSURE STATEMENT)				Applicant(s): Falt, et. al.			
				Filing Date: October 1, 2003		Group: 1638	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.		Date		Name	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.		Publication Date		Country	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	1.	Brand, A.H. et al., "Targeted gene expression as means of altering cell fates and generating dominant phenotypes", <i>Development</i> , 118:401-415 (1993).					
	2.	Chan, H. et al., " <i>Drosophila</i> models of human neurogenerative disease", <i>Cell Death Differ.</i> , 7:1075-1080 (2000).					
	3.	Feany, M.B. et al., "A <i>Drosophila</i> model of parkinson's disease", <i>Nature</i> , 404:394-398 (2000).					
	4.	Fernandez-Funez, P. et al., "Identification of genes that modify ataxin-1-induced neurodegeneration", <i>Nature</i> , 408:101-106 (2000).					
	5.	Fortini, M.E. et al., "Modeling human neurodegenerative diseases in <i>Drosophila</i> ", <i>Trends Genet.</i> 16(4):161-167 (2000)					
	6.	Jackson, G.R. et al., "Polyglutamine-Expanded Human Huntingtin Transgenes Induce Degeneration of <i>Drosophila</i> Photoreceptor Neurons", <i>Neuron</i> , 21:633-642 (1998).					
	7.	Kazemi-Esfarjani, P. et al., "Genetic Suppression of Polyglutamine Toxicity in <i>Drosophila</i> ", <i>Science</i> , 287:1837-1840 (2000).					
	8.	Marsh, J.L. et al., "Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in <i>Drosophila</i> ", <i>Hum. Mol. Genet.</i> 9(1):13-25 (2000).					
	9.	Warrick, J.M. et al., "Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in <i>Drosophila</i> ", <i>Cell</i> 93:939-949 (1998).					
EXAMINER						DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							